New heart ultrasound dye passes early safety tests
NCT ID NCT04185246
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new contrast agent called NH002 in 36 adults with heart disease. The agent is used during heart ultrasound to make the heart's chambers and borders clearer. The main goal was to check safety by monitoring vital signs, heart activity, and allergic reactions after three different doses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Mackay Memorial Hospital
Taipei, 10449, Taiwan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart surgery in childhood: a hidden impact on speech and memory?
- A website designed to steer teens with heart defects away from vaping
- Could a hot bath after exercise help heal the heart?
- AI stethoscope aims to spot hidden heart and lung problems in children
- Can community hospitals in zambia master severe disease care?
- App-Based exercise program aims to strengthen hearts in congenital disease